{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Khan H"],"funding":["Medical College of Wisconsin Cancer Center","University of Wisconsin Carbone Cancer Center","American Cancer Society","University of Wisconsin Skin Disease Research Center","NCI NIH HHS","Dermatology Foundation","NIGMS NIH HHS"],"pagination":["3009-3018.e4"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8385748"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["29(10)"],"pubmed_abstract":["Metabolic flexibility allows cells to adapt to various environments and limits the efficacy of metabolic drugs. Therapeutic targeting of cancer metabolism relies on defining limiting requirements and vulnerabilities in the highly dynamic metabolic network. Here, we characterize the metabolic reprogramming and identify cancer-specific metabolic vulnerabilities in response to the pharmacological inhibition of mitochondrial complex I. Our work reveals the adaptation mechanism in malignant lymphocytes providing resistance against the biguanides phenformin and metformin by transcriptionally reprogramming glucose metabolism. Metabolic adaptation to complex I inhibition is mediated by mitochondrial reactive oxygen species (mROS) serving as a mitochondrial stress signal activating hypoxia-inducibl"],"journal":["Cell reports"],"pubmed_title":["Metabolic Rewiring in Response to Biguanides Is Mediated by mROS/HIF-1a in Malignant Lymphocytes."],"pmcid":["PMC8385748"],"funding_grant_id":["T32 GM008692","#P30 CA014520","#86-004-26","P30 CA014520"],"pubmed_authors":["Khan H","Yang DT","Prasad A","Jeffery J","Kittipongdaja W","Schieke SM","Roy S","Anshu A"],"additional_accession":[]},"is_claimable":false,"name":"Metabolic Rewiring in Response to Biguanides Is Mediated by mROS/HIF-1a in Malignant Lymphocytes.","description":"Metabolic flexibility allows cells to adapt to various environments and limits the efficacy of metabolic drugs. Therapeutic targeting of cancer metabolism relies on defining limiting requirements and vulnerabilities in the highly dynamic metabolic network. Here, we characterize the metabolic reprogramming and identify cancer-specific metabolic vulnerabilities in response to the pharmacological inhibition of mitochondrial complex I. Our work reveals the adaptation mechanism in malignant lymphocytes providing resistance against the biguanides phenformin and metformin by transcriptionally reprogramming glucose metabolism. Metabolic adaptation to complex I inhibition is mediated by mitochondrial reactive oxygen species (mROS) serving as a mitochondrial stress signal activating hypoxia-inducibl","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Dec","modification":"2025-04-05T15:09:25.513Z","creation":"2022-02-11T09:44:39.959Z"},"accession":"S-EPMC8385748","cross_references":{"pubmed":["31801069"],"doi":["10.1016/j.celrep.2019.11.007"]}}